245 related articles for article (PubMed ID: 2494599)
1. Can low-dosage aluminium hydroxide control the plasma phosphate without bone toxicity?
Jenkins DA; Gouldesbrough D; Smith GD; Cowie JF; Winney RJ
Nephrol Dial Transplant; 1989; 4(1):51-6. PubMed ID: 2494599
[TBL] [Abstract][Full Text] [Related]
2. Bone aluminum deposition in maintenance dialysis patients treated with aluminium-free dialysate: role of aluminium hydroxide consumption.
Heaf JG; Pødenphant J; Andersen JR
Nephron; 1986; 42(3):210-6. PubMed ID: 3945361
[TBL] [Abstract][Full Text] [Related]
3. Calcium carbonate as a phosphate binder in dialysis patients: evaluation of an enteric-coated preparation and effect of additional aluminium hydroxide on hyperaluminaemia.
Ittel TH; Schäfer C; Schmitt H; Gladziwa U; Sieberth HG
Klin Wochenschr; 1991 Jan; 69(2):59-67. PubMed ID: 2027271
[TBL] [Abstract][Full Text] [Related]
4. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
[TBL] [Abstract][Full Text] [Related]
5. Hypophosphataemia and osteomalacia in haemodialysis patients not taking phosphate binders.
Ahmed KY; Varghese Z; Meinhard EA; Baillod RA; Skinner RK; Wills MR; Moorhead JF
Adv Exp Med Biol; 1977; 81():581-90. PubMed ID: 899942
[No Abstract] [Full Text] [Related]
6. Newcastle bone disease in Hong Kong: a study of aluminum associated osteomalacia.
Chan MK; Varghese Z; Li MK; Wong WS; Li CS
Int J Artif Organs; 1990 Mar; 13(3):162-8. PubMed ID: 2189835
[TBL] [Abstract][Full Text] [Related]
7. Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia.
O'Donovan R; Baldwin D; Hammer M; Moniz C; Parsons V
Lancet; 1986 Apr; 1(8486):880-2. PubMed ID: 2870354
[TBL] [Abstract][Full Text] [Related]
8. [Calcium carbonate for the treatment of hyperphosphatemia in chronic hemodialysis patients].
Kiss D; Battegay M; Meier C; Lyrer A
Schweiz Med Wochenschr; 1990 Mar; 120(9):295-8. PubMed ID: 2315655
[TBL] [Abstract][Full Text] [Related]
9. Iatrogenic osteomalacia and myopathy due to phosphate depletion.
Baker LR; Ackrill P; Cattell WR; Stamp TC; Watson L
Br Med J; 1974 Jul; 3(5924):150-2. PubMed ID: 4843652
[TBL] [Abstract][Full Text] [Related]
10. [Clinical study of concerning factors of decreased bone mineral content in hemodialysis patients].
Kohara N
Nihon Jinzo Gakkai Shi; 1991 Jun; 33(6):587-96. PubMed ID: 1920939
[TBL] [Abstract][Full Text] [Related]
11. The desferrioxamine test predicts bone aluminium burden induced by A1(OH)3 in uraemic patients but not mild histological osteomalacia.
Fournier A; Fohrer P; Leflon P; Moriniere P; Tolani M; Lambrey G; Demontis R; Sebert JL; Van Devyver F; Debroe M
Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():371-6. PubMed ID: 3991525
[TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of bone aluminum content and bone histology in patients on chronic hemodialysis and hemofiltration.
Sebert JL; Fournier A; Leflon P; Fohrer P; de Frémont JF; Morinière P; Galy C; Marie A; Demontis R; Boudailliez B
Nephron; 1986; 42(1):34-40. PubMed ID: 3941748
[TBL] [Abstract][Full Text] [Related]
13. Serum aluminium in haemodialysis patients: relation to osteodystrophy, encephalopathy and aluminium hydroxide consumption.
Heaf JG; Nielsen LP
Miner Electrolyte Metab; 1984; 10(6):345-50. PubMed ID: 6503890
[TBL] [Abstract][Full Text] [Related]
14. High-dose calcium carbonate with stepwise reduction in dialysate calcium concentration: effective phosphate control and aluminium avoidance in haemodialysis patients.
Sawyer N; Noonan K; Altmann P; Marsh F; Cunningham J
Nephrol Dial Transplant; 1989; 4(2):105-9. PubMed ID: 2496350
[TBL] [Abstract][Full Text] [Related]
15. [Iatrogenic aluminum osteopathy in a uremic infant].
Koch H; Reich H; Franke D; Delling G
Monatsschr Kinderheilkd; 1986 May; 134(5):279-81. PubMed ID: 3724766
[TBL] [Abstract][Full Text] [Related]
16. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
17. Comparison of calcium carbonate and aluminium hydroxide as phosphate binders on biochemical bone markers, PTH(1-84), and bone mineral content in dialysis patients.
Jespersen B; Jensen JD; Nielsen HK; Lauridsen IN; Andersen MJ; Poulsen JH; Gammelgaard B; Pedersen EB
Nephrol Dial Transplant; 1991; 6(2):98-104. PubMed ID: 1857534
[TBL] [Abstract][Full Text] [Related]
18. Aluminium-induced osteomalacia in severe chronic renal failure (SCRF).
Visser WJ; Van de Vyver FL
Clin Nephrol; 1985; 24 Suppl 1():S30-6. PubMed ID: 3915958
[TBL] [Abstract][Full Text] [Related]
19. Bone disease in renal failure. Clinical and histomorphometric studies.
Nilsson P
Scand J Urol Nephrol Suppl; 1984; 84():1-68. PubMed ID: 6393322
[TBL] [Abstract][Full Text] [Related]
20. Prevention of osteitis fibrosa, aluminium bone disease and soft-tissue calcification in dialysis patients: a long-term comparison of moderate doses of oral calcium +/- Mg(OH)2 vs Al(OH)3 +/- 1 alpha OH vitamin D3.
Morinière P; Boudailliez B; Hocine C; Belbrik S; Renaud H; Westeel PF; Solal MC; Fournier A
Nephrol Dial Transplant; 1989; 4(12):1045-53. PubMed ID: 2517325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
